IndSwift

Medicines/Products by Categories

BRIEF PROFILE OF IND SWIFT GROUP

Ind Swift Group, a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

ORGANISATIONAL STRUCTURE-IND SWIFT GROUP

Ind Swift group, as pharmaceutical business model is one of India's largest manufacturer of high growth multi segment pharmaceutical finished dosage forms and API's (Active Pharmaceutical Ingredients).

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, Ointments, Injectable, Liquids & Dry Syrup (all latest formulations with a marketing network.

Our API section has spread over an area of 7 Lac sq. ft, carried out at 3 different state-of-th-art units approved by USFDA and E.U regulatory authorities with a marketing network spread over in 40 countries viz. Europe/USA/Middle East possessing 2 patented molecules with 11 molecules in offing It possesses 50% exports percentage. Ind Swift entered into bulk drugs with its own Research and Development facility and laboratories at Derabassi. Later on, those units got USFDA approval and got the process patents for Clarithromycin for US and allied markets and further five more patent drugs await clearance for the moment. A joint venture with Iran has also been signed for the manufacturing of Clarithormycin with construction underway and will start operations by the end 2008. The company has offices and supplies pharma drugs not only in India but overseas as well.

R & D (Research & Development)

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and Researchers.

A well accepted expertise in NDDS, in India and the world over.
A US patent for Clarie OD, with a market size of US$ 300 million.
Another patent for Fexofenadine ODT with a market size of US$ 2.5 billion.
Development of 10 new molecules with a market size of US$ 6 billion.

Ind Swift's efforts and achievements in taste masking of macrolides was India's first......... and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the Company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Our R & D's Achievement

Its pioneering R & D efforts have led to the creation and introduction of blockbuster drugs like:

Atrovastatin – One of the most effective cholesterol lowering drugs with an estimated market size of US$ 12 billion.
Nitazoxanide – a wonder, one of its kind anti-diarroheal with a market of US$ 6 billion.
Pioglitazone – an anti-diabetic drug ranked among the first five in its Therapeutic segment.
Arthrill – an herbal wonder for the treatment of Arthritis.
Anaproct – an ayurvedic product providing relief from piles within 24 hours with no allopathic cometitor.

Ind-Swift has strategic R&D and manufacturing alliances with companies in the United Kingdom, Turkey and Iran.

In formulations front, Ind Swift proud of its multifarious achievements viz. Neurophen forte, a composition of Ibuprofen & Acetamenofen. Ind Swift is the company to give this composition to the country for the first time. Another formulation i.e. Suprox SR, a composition of Isoxprine Hel, sustained release tablets was first time launched in India in tablet form. Mouth dissolving tablets technology was introduced for the first time in India by Ind Swift. The company today stands second in the north in pharmaceutical sector.

It is an honour to add here that we are among the top 500 fortune companies of India and have been ranked at No. 35 by IMS/ORG in Pharmaceutical industry & possess a portfolio of 650 products with presence in high growth therapeutic segments of Cardiology, Diabetology, Anti depressant, anti-allergic, Anti- infective, Neurology & Oncology with a nation wide distribution network comprising 1200 marketing professional working with 12 marketing divisions, 50 offices in India, 3000 super stockists and stockists.

Our sparkling footsteps on diversification front are as under mentioned:-

Infrastructures: Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Publishing & Packagings: Ind Swift by virtue of its strong business acumen has also put a step in the field of publications also in the name and style of Mansa Print & Publishers Ltd's which has hovered over the industry within a very short span by coming up with Aluminum Division in 2007 wherein the manufacturing & printing of various type of packaging material viz. Aluminium collapsible tubes, mono cartons etc is undertaken and now will add a new feather in ISL's cap by launching a separate unit for PE, Lami tubes and PET bottles. Not only this it further proposes to come up with a stationary unit for which the building has already been constructed. The total plan will increase Mansa's sale by 200%.

Another project for Injunction moulding has also been proposed. Both these plants have a total layout plan out of Rs. 40 crore.

Media & Publication: Ind Swift has focused up in media & publication sector under the name “Ind Swift Communications Pvt. Ltd” with its illustrious and infomercial journals as “Pharmabuzz”, “Trendz”, ADI (Drug Index), Agrovet and further proposes to come up with General magazines and tabloids.

Software Development: Ind Swift has also entered into IT & software with their initial projects of developing web portals, search engines optimizations, website development, software & ERP systems development. Its initial portals which are already on air are OTC mart.com, buysweethome.com, painting &photographs.com, doctorsonline.com & ayurvedaherbs.com.

Our sparkling footsteps on diversification in Education front are under-mentioned:-

Swift Institute:Our Swift Institute is exclusively diverse from the plenteous private educational institutions cropping up in North India, having world class infrastructure, faculty, laboratories and other facilities. To initiate with, we have instituted six months Industrial Training Courses in Pharmaceutical Sciences, for Operator Level Training which has enabled the 10th or 10+2 students to start a career in the booming Pharma industry & until now we have already trained and placed more than 400 students at Ind Swift which we feel contributes a lot to the skilled manpower starving industry.

Swift Fundamental Research Education : SFRE (Swift Fundamental Research Education ) is a society made under the banner of Ind Swift which has recently laid an another step on the diversification spree and has forayed up with a Pharmacy college at Rajpura with the name & style of “Swift School of Pharmacy”, and is a unique state of art with the best of specifications also. With this new venture of IND SWIFT, we have been ranked as the pioneers in this part of the country having a solid pharmaceutical industrial background to come up with our own Pharmacy & Nursing institute. The institute will be operational from current session year 2008-2009 with an intake of 60 students in the field of Pharmacy and Nursing each, in the first year by virtue of its high resourcefulness and know-how and will provide quality education to one and all, aspiring careers in the field of Pharmacy.

We manifest to be imminent with Engineering, Architecture, Management, Hotel Management, General Management, Schools of Dentistry, Ayurveda Physiotherapy and Medical Technology and finally a Medical College with its functioning operational by 2010-11 under the budget of Rs. 250 Crore with a specific target on Medical Tourism.

Domestic Marketing:The company's new division “diagnosis” dealing in medical equipments & devices thereby focusing personal health care was launched in December 2007 and has reflected promising performance & is growing leaps and bounds from the first month of its launch which has given utmost confidence to the company to get the aggrandized sales and contribution not in the current year but in the forthcoming years as well. Not only this, the division projects to achieve a business objective of 10 crores with impressive contribution to ISL and possesses a strategy of adding up few other specialty products in the existing range of personal health care & Academic Body model series.

Another division launched by your company is “Animal Health Care” which is an absolutely new concept with outsourced marketing and has proved out to be an individual profit center.

Apart from struggling uphill for the current range of products our Ethical marketing have introduced those products during the year which are monopolistic in nature viz. Cirrholiv which has proved out to be a remedy in Hepatitis and other liver disorders. Other brands introduced by your company during the year are Topclav 625, Emtee 25 and Timcol Eye Drops.

In Generics, your company emerged as the 2nd rank Pharma Generic company and has attained the fame of featuring its few brands (Amyclox, Swimox, Oxo, Swiflox and Cafzone (already achieving the sales growth over 25 crore) as the top brands in Generics. Company's brand Swimox has been enlisted among leading brands in ORG IMS and Amyclox leads the que among top 300 brands of the industry.

Annual growth for the company during the year is 36.73%.

RESEARCH & DEVELOPMENT

Looking at the current scenario where the pharmaceutical majors are engaged in the advancement of R & D, we have been competent enough to work out on non infringing processes, Novel Drug Delivery Systems, dossiers, stability data profiling, conceptualization of new molecules (and therefore a nmber of product combination have been developed and are ready to be launched by our marketing divisions). Your company's R&D is involved in creating international opportunities and alliances for CRAMS (specially contract Research) to make it contribute 30% of profits. Till date two major contracts were signed an have been delivered. We are hopeful to attain more contracts on product development and stability data profiling. Apart from this, we are applying invincible efforts to get approvals for a Bio-equivalence centre which will further strengthen the basket of R&D. To strengthen the CRAMS business to the exquisite level, your company is tying up with various academic institutes.

By virtue of the hard endeavors of R&D all through the year, unique combinations/NDDS of single molecule are around the corner and awaiting launch by this year. Apart from this, R&D is emphasizing on a major area which is cost Reduction. More than 5% of total revenues have been planned to spend on the company's R&D and the same will be continued in the forthcoming years as well.

New Manufacturing Facilities:

Apart from its existing plants in tax exempted zone of J&K and Baddi, duly certified and approved by WHO GMP, your company has successfully commissioned another Manufacturing facility at the same tax exempted zone and green plains of Baddi during the year. This new manufacturing facility inaugurated in August 2007, is for soft Gelatin Encapsulation with an annual capacity of 36 Crore and will not only make us almost self sufficient in soft gelatin manufacturing but will unquestionably dedicated a bit of spare capacities for contract manufacturing as well.

Company's manufacturing unit at Parwanoo has also been upgrades as per WHO Standards.

Company's Global Business Unit (GBU) at Derabassi has got MHRA & TGA approval.

These new facilities will augment the company's efforts to tap the regulated markets and strengthen the company's growing CRAMS business which is expected to accounts for 30-40% of its bottom line over the next four years. Your company has been certified for ISO 9000:2001 also during the year.